BAVA:CPH
Bavarian Nordic A/S
DKK 237.40
arrow_upward
+0.25%(+0.60) 1D
Oct 14, 10:40:20 AM GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKK 236.40
High
DKK 238.00
Low
DKK 236.20
Mkt. cap
19.12B
Avg. vol.
179.21K
Volume
85.79K
52-wk high
DKK 243.70
52-wk low
DKK 171.30
Shares outstanding
79.27M
No. of employees
2K
Open
DKK 236.40
High
DKK 238.00
Low
DKK 236.20
Mkt. cap
19.12B
Avg. vol.
179.21K
Volume
85.79K
52-wk high
DKK 243.70
52-wk low
DKK 171.30
Shares outstanding
79.27M
No. of employees
2K
News stories
From web sources and news partners
FXLeaders
·
1 hour ago
Dow Futures Driven by Bank Earnings, Crude Oil & US Bond Yields
TradingView
·
1 hour ago
SPX: S&P 500 Parked Just Below Record as Traders Go Risk-Off Ahead of September CPI
StreetInsider
·
11 minutes ago
Global S&P Futures mixed in premarket
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com